• The Deinodrop technology will be co-developed by ESPCI and DEINOVE to accelerate the discovery and identification of bacteria producing new antibiotics.
  • The project aims to develop a technology for sorting bacteria into droplets and screening at very high rates.
  • This will facilitate the detection of antibiotic activities and allows single-cell screening giving access to species said to be non-cultivable.
  • The ANR granted Deinodrop €300k in funding, following a very demanding selection process.

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announces that it has obtained, jointly with ESPCI Paris*, a €300k grant from the ANR** for the co-development of an innovative system for the isolation, culture and screening of bacteria.

The Deinodrop partnership research project, involving DEINOVE and ESPCI Paris, was selected by the ANR as part of the call for collaborative research projects in the field of Healthcare technologies. This two-year project has been granted €300k in funding.

This project, which will support the AGIR program, aims to develop an innovative microfluidic sorting system, into drops containing environmental bacteria, in which each drop constitutes a microreactor. Once developed, this technology will offer many benefits to accelerate research and increase the success rate of the AGIR program:

  • Increased screening sensitivity, for better detection of antibiotics of interest;
  • Increased bacterial screening and sorting rate, up to 800 drops per second, while optimizing the amount of reagents used;
  • Ability to detect, sort and analyze bacteria said to be non- cultivable under conventional laboratory conditions.

"We are proud that the DEINODROP project has been selected by the ANR. Only 15% of the projects submitted are selected, obtaning this funding rewards the quality of our technology " says Raphaël CALBRIX, Head of the DEINOVE Banking and Robotics platform. "Our objective is to develop a breakthrough technology in bacterial culture and selection in order to be able to analyze considerable quantities of microorganisms and discover new antibiotic activities that could address the major challenge of antibiotic resistance. » 


* ESPCI Paris: Paris Institute of industrial physics and chemistry

** ANR: French National Research Agency